Therapy-activated stromal cells can dictate tumor fate

In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerbel, Robert S., Shaked, Yuval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2016
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154951/
https://www.ncbi.nlm.nih.gov/pubmed/27881735
http://dx.doi.org/10.1084/jem.20161845
_version_ 1782474920287010816
author Kerbel, Robert S.
Shaked, Yuval
author_facet Kerbel, Robert S.
Shaked, Yuval
author_sort Kerbel, Robert S.
collection PubMed
description In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.
format Online
Article
Text
id pubmed-5154951
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-51549512017-06-12 Therapy-activated stromal cells can dictate tumor fate Kerbel, Robert S. Shaked, Yuval J Exp Med News In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis. The Rockefeller University Press 2016-12-12 /pmc/articles/PMC5154951/ /pubmed/27881735 http://dx.doi.org/10.1084/jem.20161845 Text en Copyright © 2016 Kerbel and Shaked This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle News
Kerbel, Robert S.
Shaked, Yuval
Therapy-activated stromal cells can dictate tumor fate
title Therapy-activated stromal cells can dictate tumor fate
title_full Therapy-activated stromal cells can dictate tumor fate
title_fullStr Therapy-activated stromal cells can dictate tumor fate
title_full_unstemmed Therapy-activated stromal cells can dictate tumor fate
title_short Therapy-activated stromal cells can dictate tumor fate
title_sort therapy-activated stromal cells can dictate tumor fate
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154951/
https://www.ncbi.nlm.nih.gov/pubmed/27881735
http://dx.doi.org/10.1084/jem.20161845
work_keys_str_mv AT kerbelroberts therapyactivatedstromalcellscandictatetumorfate
AT shakedyuval therapyactivatedstromalcellscandictatetumorfate

Ejemplares similares